Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.45 |
| ▸ | CSF1R | P07333 | 6/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881648 | 0.82 | MAPK1 (0.40) | EGFRMAPK1MAPTAHRHTT | |
| SCHEMBL29058795 | 0.80 | CSF1R (0.61) | EGFRCSF1RMAPK1CYP3A4LMNA | |
| SCHEMBL30395651 | 0.80 | CSF1R (0.61) | EGFRCSF1RMAPK1CYP3A4LMNA | |
| SCHEMBL2296572 | 0.74 | CCNC (0.45) | EGFRAHRLMNAPTK2 | |
| SCHEMBL4007231 | 0.74 | MAPT (0.78) | EGFRMAPK1MAPTAHRHTT | |
| SCHEMBL28470356 | 0.73 | PRKDC (0.62) | PRKDC | |
| SCHEMBL4890763 | 0.71 | MAPT (0.52) | MAPK1MAPTAHRHTTPRKDC | |
| SCHEMBL4882141 | 0.71 | MAPT (0.57) | EGFRMAPK1MAPTAHRHTT | |
| SCHEMBL4013688 | 0.70 | MAPK1 (0.67) | MAPK1MAPTAHRHTTCYP3A4 | |
| SCHEMBL24340084 | 0.68 | PRKDC (0.67) | CSF1RMAPK1PRKDCCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1748991-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105761-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | EIF2AK2, MAVS, IRF3 | EGFR 3952/4885CSF1R 2947/4885MAPK1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.